← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Immunochem Therapeutics, Llc
Newton, MA
$6,838,362
Total funding
5
Grants
Funding over time
peak $1.4M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,838,362 · 5
By mechanism
R44$6,613,474 · 4
R42$224,888 · 1
Investigators at Immunochem Therapeutics, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Development of a novel anti-neuroinflammatory experimental therapeutic for epilepsy and Alzheimer's risk$1,248,699
R44 · FY2024 · AG
Development of a novel anti-neuroinflammatory experimental therapeutic for epilepsy and Alzheimer's risk$1,209,751
R44 · FY2025 · AG
First-in-human study of MW151, a novel drug targeting neuroinflammation$1,157,853
R44 · FY2019 · AG
Mitigation of Radiation Therapy Induced Neuroinflammation and Cognitive Dysfunction$777,049
R44 · FY2021 · CA
Mitigation of Radiation Therapy Induced Neuroinflammation and Cognitive Dysfunction$722,072
R44 · FY2022 · CA
First-in-human study of MW151, a novel drug targeting neuroinflammation$499,320
R44 · FY2018 · AG
Novel anti-neuroinflammatory drug for aneurysmal subarachnoid hemorrhage (aSAH)$498,363
R44 · FY2022 · NS
Development of a novel anti-neuroinflammatory experimental therapeutic for epilepsy and Alzheimer's risk$450,367
R44 · FY2021 · AG
Mitigation of Radiation Therapy Induced Neuroinflammation and Cognitive Dysfunction$224,888
R42 · FY2019 · CA
Development of a novel anti-neuroinflammatory experimental therapeutic for epilepsy and Alzheimer's risk$50,000
R44 · FY2025 · AG